Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Launch of VersaLab™ Portable

05/26/2021 | 02:01am EDT

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the expansion of its VersaLab™ portfolio with the launch of VersaLab™ Portable to provide an additional level of support in near-patient testing environments.

VersaLab™ was launched in December 2020 to support private sector testing of infectious diseases, initially focused on COVID-19. Novacyt added to the VersaLab™ portfolio in March 2021 with the launch of VersaLab™ mobile processing laboratories.

Novacyt believes that VersaLab™ Portable is an important addition to its commercial strategy as the Company looks to expand its reach in private sector testing, especially in overseas markets. The product is a “PCR lab in a box” and as such comes with all the equipment required to provide near-patient PCR testing using Novacyt’s PROmate™ workflow in non-clinical settings, such as offices and workplaces.

VersaLab™ Portable has been designed specifically with a focus on small to medium organisations, which represent a growing market opportunity for Novacyt. Other potential applications include sport events and facilities, education facilities, the leisure industry, humanitarian bases and retail.

PROmate™ is the only rapid direct-to-PCR COVID-19 assay approved by the Department of Health and Social Care’s Technology Validation Group. PROmate’s™ unique workflow allows Novacyt to provide rapid results to patients in under 80 minutes, saving time and minimising the risk of infection spreading.

Graham Mullis, Chief Executive Officer of Novacyt, commented:

“When we launched VersaLab™ our aim was to bring PCR technology closer to patients. The initial market response to the portfolio is encouraging and the Company looks to increase its promotion during the second half of 2021. With VersaLab™ Portable we can broaden access to affordable testing in areas that lack the infrastructure of laboratory-based testing whilst still providing optimum results from gold standard PCR reagents. We believe that VersaLab™ Portable can support organisations, including small to medium businesses, offer onsite testing as lockdowns begin to ease internationally.”

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com


ę Business Wire 2021
All news about NOVACYT
06/29NOVACYT : Expansion of PathFlow« COVID-19 lateral flow test portfolio
PU
06/29NOVACYT : Rapport annuel et comptes Novacyt pour l'exercice clos en décembre 202..
PU
06/29Novacyt S.A. Announces Expansion of Pathflow Covid-19 Lateral Flow Test Portf..
CI
06/22GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resour..
06/22London Shares Trade Flat; Crude Gains Lift Oil Stocks
DJ
06/22NOVACYT : 2020 Management Report
PU
06/22NOVACYT : 2020 Group Consolidated Accounts
PU
06/22NOVACYT : Full year 2020 results and update on growth strategy
PU
06/22NOVACYT : Earnings Flash (NCYT.L) NOVACYT S.A. Posts FY20 Revenue GBP277.2M
MT
06/22NOVACYT : Earnings Flash (NCYT.L) NOVACYT S.A. Reports FY20 EPS GBP1.94
MT
More news
Financials
Sales 2021 95,4 M 113 M 113 M
Net income 2021 70,0 M 82,6 M 82,6 M
Net cash 2021 109 M 129 M 129 M
P/E ratio 2021 4,45x
Yield 2021 -
Capitalization 273 M 323 M 323 M
EV / Sales 2021 1,72x
EV / Sales 2022 0,99x
Nbr of Employees 174
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 3,87 €
Average target price 8,88 €
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-60.50%341
MODERNA, INC.221.50%88 312
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555